Aktis Oncology Inc., a clinical-stage biotechnology company that counts Eli Lilly & Co. among its backers, raised $317.7 million in an initial public offering priced at the top of the marketed range.
The Boston-based firm sold 17.65 million shares at $18 each, according to a statement Thursday. The listing also drew interest from Eli Lilly for about $100 million shares, according to an earlier filing with the US Securities and Exchange Commission.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.